menu
    • menu
    [{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lazertinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yuhan Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"J Ints Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"JIN-A04","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Yuhan Corporation","amount2":0.33000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Yuhan Corporation \/ Yuhan Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Yuhan Corporation \/ Yuhan Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Yuhan Corporation

    Menu

    Yuhan Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yuhan Corporation

                            South Korea arrow
                            BioFlorida Conference
                            Not Confirmed

                            Yuhan Corporation

                            South Korea arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JIN-A04

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : J Ints Bio

                            Deal Size : $325 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Yuhan Corporation and J INTS BIO Inked a Licensing Agreement for A New Drug Candidate Targeting HER2 NSCLC

                            Details : The license agreement is for JIN-A04, an oral Tyrosine Kinase Inhibitor (TKI) targeting non-small cell lung cancer carrying HER2 mutations. There is currently no oral drug approved to date.

                            Brand Name : JIN-A04

                            Molecule Type : Undisclosed

                            Upfront Cash : $1.9 million

                            May 31, 2023

                            Lead Product(s) : JIN-A04

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : J Ints Bio

                            Deal Size : $325 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yuhan Corporation

                            South Korea arrow
                            BioFlorida Conference
                            Not Confirmed

                            Yuhan Corporation

                            South Korea arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lazertinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Yuhan’s Lung Cancer Treatment Lazertinib Wins Approval

                            Details : The Ministry of Food and Drug Safety announced its approval for the third-generation non-small cell lung cancer treatment, Leclaza. Leclaza is a swallowable tablet that can be taken at a fixed time every day, regardless of meals.

                            Brand Name : Leclaza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 18, 2021

                            Lead Product(s) : Lazertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth